News
Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker
August 11th 2025New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.
Importance of Patient Selection and Future Therapies in Alzheimer Treatment
August 10th 2025In the third episode, Salloway emphasizes the need for careful patient selection when prescribing donanemab to minimize serious risks, highlighting the value of the newly approved safer dosing regimen. Supported by Eli Lilly.
Maintaining Efficacy in Safer Donanemab Dosing Regimen
August 9th 2025Dementia expert Stephen Salloway, MD, PhD, overviews the stepwise donanemab regimen approved by the FDA, citing how it not only reduces ARIA rates but preserves the same level of amyloid reduction as the original dosing. Supported by Eli Lilly.
Monitoring Long-Term Efficacy of Migraine Wearable Device Over 3 Years: Alit Stark-Inbar, PhD
August 8th 2025The corporate vice president of medical information and research at Theranica discussed long-term findings presented at AHS 2025 covering the company’s Nerivio remote electrical neuromodulation device for patients with migraine. [WATCH TIME: 5 minutes]
Openwater’s LIFU Technology at MIT: A New Era for Consciousness and Neurological Care
August 7th 2025Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.
Donanemab Receives CHMP Positive Opinion as Treatment for Early Symptomatic Alzheimer Disease
August 7th 2025Donanemab has received a positive opinion from the European Medicines Agency’s CHMP for the treatment of early symptomatic Alzheimer disease, bringing Eli Lilly’s anti-amyloid therapy one step closer to approval in the European Union.
Targeting SIGLEC10 With ONC-841: A Novel Mechanism in Alzheimer Disease Treatment
August 7th 2025Yang Liu, PhD, co-founder, CEO, and chief scientific officer of OncoC4, provided commentary on the rationale and promising preclinical data behind ONC-841, a novel anti-SIGLEC10 antibody targeting amyloid and tau in Alzheimer disease.
Highlighting Research Progress in Tau-Targeting Therapy for Alzheimer Disease: Diana Gallagher, MD
August 6th 2025At AAIC 2025, the head of AD, MS and Immunology Development Units at Biogen discussed ongoing research efforts targeting tau pathology in AD, specifically the company's investigational candidate BIIB080. [WATCH TIME: 6 minutes]
Factors to Consider When Choosing the Right Disease-Modifying Therapy for Newly Diagnosed MS
August 6th 2025Gabrielle Macaron, MD, assistant professor of neuroscience at Université de Montréal, discussed the nuanced clinical decision-making involved in initiating a DMT for patients newly diagnosed with MS.
The Shift in CIDP Treatment Toward Individualized, Evidence-Based Care: Karissa Gable, MD
August 6th 2025The neurologist at Duke Health provided insights on how chronic demyelinating inflammatory polyneuropathy treatment is evolving toward biomarker-driven, personalized approaches at the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 2 minutes]
Exploring GLP-1 Receptor Agonists for Idiopathic Intracranial Hypertension: Dennis Rivet, MD
August 5th 2025The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University discussed new data supporting the potential of GLP-1 RAs as a non-surgical option for idiopathic intracranial hypertension. [WATCH TIME: 3 minutes]
